Bullish Options Positioning in Gilead Sciences (GILD) Targets Upside in Shares Over the Coming Months -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences' (GILD) BIKTARVY Receives FDA Approval
February 7, 2018 2:11 PM ESTGilead Sciences' (NASDAQ: GILD) BIKTARVY Receives FDA Approval
From the FDA
New Drug Application (NDA): 210251
Company: GILEAD SCIENCES INC
Gilead Sciences (GILD) PT Lowered to $84 at Morgan Stanley
February 7, 2018 8:06 AM ESTMorgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $87.00) while maintaining a Equalweight rating.
... MoreGilead Sciences (GILD) PT Lowered to $83 at Leerink Partners
February 7, 2018 7:10 AM ESTLeerink Partners lowered its price target on Gilead Sciences (NASDAQ: GILD) to $83.00 (from $86.00) while maintaining a Market Perform rating.
... MoreGilead Sciences (GILD) PT Raised to $80 at UBS
February 7, 2018 6:30 AM ESTUBS raised its price target on Gilead Sciences (NASDAQ: GILD) to $80.00 (from $77.00) while maintaining a Neutral rating.
... MoreGilead Sciences (GILD) PT Lowered to $90 at Deutsche Bank
February 7, 2018 6:02 AM ESTDeutsche Bank lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $91.00) while maintaining a Buy rating.
... MoreGilead Sciences (GILD) PT Raised to $105 at Citi
February 7, 2018 5:51 AM ESTCiti raised its price target on Gilead Sciences (NASDAQ: GILD) to $105.00 (from $103.00) while maintaining a Buy rating.
... MoreGilead Sciences (GILD) Raises Quarterly Dividend 9.6% to $0.57; 2.8% Yield
February 6, 2018 4:04 PM ESTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.57 per share, or $2.28 annualized. This is a 9.6% increase from the prior dividend of $0.52.
The dividend will be payable on March 29, 2018, to stockholders of record on March 16, 2018, with an ex-dividend date of March 15,... More
Gilead Sciences (GILD) Q4 Revenue Tops Views, Offers Guidance
February 6, 2018 4:03 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.74 billion.
GUIDANCE:
Gilead Sciences sees FY2018 revenue of $20-21 billion, versus the consensus of... More
